Long-term oncologic outcomes of pulmonary metastasectomy for lung-confined recurrent endometrial cancer: a single-institution case series.
- 1Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto City, Kumamoto, Japan.
Abstract
Pulmonary recurrence in endometrial cancer is generally regarded as a manifestation of systemic disease and is primarily managed with systemic therapy. However, the clinical significance of lung-confined recurrent endometrial cancer and the role of pulmonary metastasectomy remain uncertain. To evaluate the long-term oncologic outcomes of pulmonary metastasectomy in patients with lung-confined recurrent endometrial cancer and to explore whether lung-confined recurrence represents a clinically distinct pattern of recurrence. This retrospective single-institution case series included consecutive patients with lung-confined recurrent endometrial cancer who underwent pulmonary metastasectomy between January 2005 and July 2026. Clinicopathological characteristics, long-term oncologic outcomes, and perioperative outcomes were evaluated. Six patients underwent pulmonary metastasectomy for lung-confined recurrent endometrial cancer. The median interval from primary surgery to first pulmonary recurrence was 45.5 months (range, 19-227 months). Complete (R0) pulmonary resection was achieved in all patients without severe surgery-related adverse events. During a median follow-up of 103.5 months (range, 47-250 months) from primary surgery, all 6 patients remained alive, and 5 of 6 achieved durable disease-free status. Following the first pulmonary metastasectomy, 1 patient developed subsequent lung-confined recurrence and underwent repeat pulmonary metastasectomy, achieving additional long-term disease control. Notably, the 2 patients with synchronous bilateral pulmonary metastases also achieved durable disease-free survival following complete staged bilateral resection. Pulmonary metastasectomy may provide durable long-term disease control in carefully selected patients with lung-confined recurrent endometrial cancer. Recognition of lung-confined recurrent endometrial cancer as a clinically distinct pattern of recurrence may support a shift from routine systemic therapy alone toward a more individualized multidisciplinary treatment strategy incorporating pulmonary metastasectomy.
Related
- Risk‐Stratified Bilateral Tonsillectomy for Unilateral HPV‐Associated Tonsillar SCC: Oncologic and Functional Outcomes From a Single Institution
- Survival after pulmonary metastasectomy for pancreatobiliary carcinomas: insights from a nationwide multicenter database
- Pulmonary metastasectomy in solid tumors: a single-center experience at a tertiary referral center in the Middle East.
- Bridging the Artificial Intelligence Translation Gap in Perioperative Pulmonary and Respiratory Complications: A Practical Framework for Institution-Level Implementation
- Beyond the embryo: reframing recurrent implantation failure through immunopriming and endometrial immune dysregulation
BibTeX
@article{kawanaka2026longterm,
title = {{Long-term oncologic outcomes of pulmonary metastasectomy for lung-confined recurrent endometrial cancer: a single-institution case series.}},
author = {Minami Kawanaka and Akiho Nishimura and Takeshi Motohara},
journal = {AJOG global reports},
year = {2026},
month = oct,
doi = {10.1016/j.xagr.2026.100705},
url = {https://europepmc.org/article/MED/42999453},
note = {CC BY},
}
RIS
TY - JOUR
TI - Long-term oncologic outcomes of pulmonary metastasectomy for lung-confined recurrent endometrial cancer: a single-institution case series.
AU - Minami Kawanaka
AU - Akiho Nishimura
AU - Takeshi Motohara
PY - 2026
DA - 2026/10/07
JO - AJOG global reports
DO - 10.1016/j.xagr.2026.100705
UR - https://europepmc.org/article/MED/42999453
AB - Pulmonary recurrence in endometrial cancer is generally regarded as a manifestation of systemic disease and is primarily managed with systemic therapy. However, the clinical significance of lung-confined recurrent endometrial cancer and the role of pulmonary metastasectomy remain uncertain. To evaluate the long-term oncologic outcomes of pulmonary metastasectomy in patients with lung-confined recurrent endometrial cancer and to explore whether lung-confined recurrence represents a clinically distinct pattern of recurrence. This retrospective single-institution case series included consecutive patients with lung-confined recurrent endometrial cancer who underwent pulmonary metastasectomy between January 2005 and July 2026. Clinicopathological characteristics, long-term oncologic outcomes, and perioperative outcomes were evaluated. Six patients underwent pulmonary metastasectomy for lung-confined recurrent endometrial cancer. The median interval from primary surgery to first pulmonary recurrence was 45.5 months (range, 19-227 months). Complete (R0) pulmonary resection was achieved in all patients without severe surgery-related adverse events. During a median follow-up of 103.5 months (range, 47-250 months) from primary surgery, all 6 patients remained alive, and 5 of 6 achieved durable disease-free status. Following the first pulmonary metastasectomy, 1 patient developed subsequent lung-confined recurrence and underwent repeat pulmonary metastasectomy, achieving additional long-term disease control. Notably, the 2 patients with synchronous bilateral pulmonary metastases also achieved durable disease-free survival following complete staged bilateral resection. Pulmonary metastasectomy may provide durable long-term disease control in carefully selected patients with lung-confined recurrent endometrial cancer. Recognition of lung-confined recurrent endometrial cancer as a clinically distinct pattern of recurrence may support a shift from routine systemic therapy alone toward a more individualized multidisciplinary treatment strategy incorporating pulmonary metastasectomy.
SN - 2666-5778
ER -